Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Iris color as a prognostic factor in ocular melanoma.

Regan S, Judge HE, Gragoudas ES, Egan KM.

Arch Ophthalmol. 1999 Jun;117(6):811-4.

PMID:
10369595
2.

Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma.

Li W, Gragoudas ES, Egan KM.

Arch Ophthalmol. 2003 Jan;121(1):68-72.

PMID:
12523887
4.

Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma.

Li W, Gragoudas ES, Egan KM.

Arch Ophthalmol. 2000 Aug;118(8):1066-70.

PMID:
10922199
5.

Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26.

Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma Study Group..

Arch Ophthalmol. 2005 Dec;123(12):1639-43.

PMID:
16344433
6.
8.

Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).

Rouberol F, Roy P, Kodjikian L, Gérard JP, Jean-Louis B, Grange JD.

Am J Ophthalmol. 2004 May;137(5):893-900.

PMID:
15126155
9.

Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W.

Trans Am Ophthalmol Soc. 2002;100:43-8; discussion 48-9.

11.

Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement.

Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW.

Am J Ophthalmol. 1999 May;127(5):579-89.

PMID:
10334352
12.

The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19.

Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, Diddie KR, Engstrom RE Jr, Finger PT, Hovland KR, Joffe L, Olsen KR, Wells CG; Collaborative Ocular Melanoma Study Group (COMS Group)..

Ophthalmology. 2002 Dec;109(12):2197-206. Erratum in: Ophthalmology. 2004 Aug;111(8):1514.

PMID:
12466159
13.

Outcomes of proton radiation therapy for peripapillary choroidal melanoma at the BC Cancer Agency.

Tran E, Ma R, Paton K, Blackmore E, Pickles T.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1425-31. doi: 10.1016/j.ijrobp.2011.10.017.

PMID:
22209152
14.

Post-irradiation regression of choroidal melanomas as a risk factor for death from metastatic disease.

Augsburger JJ, Gamel JW, Shields JA, Markoe AM, Brady LW.

Ophthalmology. 1987 Sep;94(9):1173-7.

PMID:
3684235
15.

Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.

Isager P, Ehlers N, Overgaard J.

Acta Ophthalmol Scand. 2004 Oct;82(5):517-25.

16.

An evaluation of the influence of reproductive factors on the risk of metastases from uveal melanoma.

Egan KM, Walsh SM, Seddon JM, Gragoudas ES.

Ophthalmology. 1993 Aug;100(8):1160-5; discussion 1166.

PMID:
8341495
17.

[The regression behavior of choroid melanoma following radiotherapy--a new prognostic parameter?].

Guthoff R, Haase J, von Domarus D, Draeger J, Lauritzen K.

Klin Monbl Augenheilkd. 1990 Jan;196(1):6-10. German.

PMID:
2313997
18.

Outcomes of iodine 125 plaque radiotherapy after initial observation of suspected small choroidal melanomas: a pilot study.

Sobrin L, Schiffman JC, Markoe AM, Murray TG.

Ophthalmology. 2005 Oct;112(10):1777-83.

PMID:
16095708
19.
20.

Childbearing history associated with improved survival in choroidal melanoma.

Egan KM, Quinn JL, Gragoudas ES.

Arch Ophthalmol. 1999 Jul;117(7):939-42.

PMID:
10408460

Supplemental Content

Support Center